4.7 Article

Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination

Journal

CLINICAL INFECTIOUS DISEASES
Volume 76, Issue 3, Pages E1062-E1070

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciac475

Keywords

children; invasive pneumococcal disease; pneumococcal conjugate vaccines; serotype distribution; streptococcus pneumoniae

Ask authors/readers for more resources

The distribution of pneumococcal serotypes in children from high-income countries has been examined. Much of the burden of invasive pneumococcal disease (IPD) is caused by serotypes in PCV15 and PCV20; including these pneumococcal conjugate vaccines (PCVs) into existing pediatric immunization programs may help reduce the incidence of IPD.
Pneumococcal serotype distribution in children from high-income countries was assessed. Much of the burden of invasive pneumococcal disease (IPD) is due to serotypes in PCV15 and PCV20; including these pneumococcal conjugate vaccines (PCVs) into existing pediatric immunization programs may help reduce IPD incidence. Background The introduction and adoption of pneumococcal conjugate vaccines (PCVs) into pediatric national immunization programs (NIPs) has led to large decreases in invasive pneumococcal disease (IPD) incidence caused by vaccine serotypes. Despite these reductions, the global IPD burden in children remains significant. Methods We collected serotype-specific IPD data from surveillance systems or hospital networks of all 30 high-income countries that met inclusion criteria. Data sources included online databases, surveillance system reports, and peer-reviewed literature. Percentage of serotyped cases covered were calculated for all countries combined and by PCV type in the pediatric NIP. Results We identified 8012 serotyped IPD cases in children <5 or <= 5 years old. PCV13 serotype IPD caused 37.4% of total IPD cases, including 57.1% and 25.2% for countries with PCV10 or PCV13 in the pediatric NIP, respectively, most commonly due to serotypes 3 and 19A (11.4% and 13.3%, respectively, across all countries). In PCV10 countries, PCV15 and PCV20 would cover an additional 45.1% and 55.6% of IPD beyond serotypes contained in PCV10, largely due to coverage of serotype 19A. In PCV13 countries, PCV15 and PCV20 would cover an additional 10.6% and 38.2% of IPD beyond serotypes contained in PCV13. The most common IPD serotypes covered by higher valency PCVs were 10A (5.2%), 12F (5.1%), and 22F and 33F (3.5% each). Conclusions Much of the remaining IPD burden is due to serotypes included in PCV15 and PCV20. The inclusion of these next generation PCVs into existing pediatric NIPs may further reduce the incidence of childhood IPD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Microbiology

PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Christian Theilacker, Mark A. Fletcher, Luis Jodar, Bradford D. Gessner

Summary: This article reviews the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) and its extended studies, highlighting the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) in preventing pneumonia and invasive pneumococcal disease in older adults. It provides valuable insights for the assessment of adult pneumococcal vaccination.

MICROORGANISMS (2022)

Article Immunology

Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England

Tendai Mugwagwa, Ahuva Averin, Mark Atwood, Reiko Sato, Andrew Vyse, James Campling, Derek Weycker, Mary Slack, Gillian Ellsbury, Diana Mendes

Summary: Replacing the 23-valent pneumococcal polysaccharide vaccine (PPV23) with the 20-valent pneumococcal conjugate vaccine (PCV20) in England would substantially reduce the burden of pneumococcal disease among at-risk adults, with modest budgetary impact.

EXPERT REVIEW OF VACCINES (2022)

Article Economics

Hospitalization costs of adult community-acquired pneumonia in England

James Campling, Hannah F. Wright, Gillian C. Hall, Tendai Mugwagwa, Andrew Vyse, Diana Mendes, Mary P. E. Slack, Gillian F. Ellsbury

Summary: The goal of this study was to estimate the current mean cost of hospitalized community-acquired pneumonia (CAP) in the UK. Based on the national healthcare database, 187,251 adults were hospitalized for CAP in 2019, with an average cost of 3,904 pounds per person and a total cost of 731 million pounds per year. Patients at high risk of CAP had higher mean costs compared to those not at risk.

JOURNAL OF MEDICAL ECONOMICS (2022)

Article Health Care Sciences & Services

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease

Diana Mendes, Ahuva Averin, Mark Atwood, Reiko Sato, Andrew Vyse, James Campling, Derek Weycker, Mary Slack, Gillian Ellsbury, Tendai Mugwagwa

Summary: The study found that replacing PPV23 with PCV20 in England could prevent more hospitalizations, save more lives, and yield lower overall costs, making it a cost-effective option for pneumococcal vaccination.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)

Article Respiratory System

Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?

Eileen M. Dunne, Catia Cilloniz, Claire von Mollendorf, Joseph Lewnard, Lindsay R. Grant, Mary P. E. Slack, Luis Jodar, Christian Theilacker, Bradford D. Gessner

Summary: This narrative review compared the effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal conjugate vaccine (PCV13) in adults. The study found that PCV13 was more effective than PPV23 in preventing pneumococcal disease and respiratory infections. The sequential PCV13/PPV23 vaccination showed little benefit over PCV13 alone. The results support the use of pneumococcal vaccines to protect against pneumococcal disease and respiratory infections in adults.

ARCHIVOS DE BRONCONEUMOLOGIA (2023)

Article Microbiology

Prevalence of Pneumococcal Serotypes in Community-Acquired Pneumonia among Older Adults in Italy: A Multicenter Cohort Study

Andrea Orsi, Alexander Domnich, Stefano Mosca, Matilde Ogliastro, Laura Sticchi, Rosa Prato, Francesca Fortunato, Domenico Martinelli, Fabio Tramuto, Claudio Costantino, Vincenzo Restivo, Vincenzo Baldo, Tatjana Baldovin, Elizabeth Begier, Christian Theilacker, Eva Agostina Montuori, Rohini Beavon, Bradford Gessner, Giancarlo Icardi

Summary: This study aimed to assess the serotype-specific epidemiology of pneumococci among hospitalized older adults in Italy. The prevalence of pneumococcal infection among hospitalized CAP cases was 13.1%, with serotypes 3, 8, 22F, and 11A being the most common. PCV20, which includes these serotypes, plays an important role in preventing pneumonia in older adults.

MICROORGANISMS (2023)

Review Microbiology

Long-Term effects of COVID-19: a review of current perspectives and mechanistic insights

Christian Lenz, Mary P. E. Slack, Kimberly M. Shea, Ralf Rene Reinert, Bulent N. Taysi, David L. Swerdlow

Summary: Although SARS-CoV-2 primarily affects the respiratory system, it can also cause a wide range of complications in the cardiovascular, pulmonary, neurological, and metabolic systems. Long-term symptoms have been observed in more than 50% of COVID-19 patients, with older age, female sex, race, ethnicity, and comorbidities being identified as risk factors. It is crucial to conduct prospective studies to understand the ongoing effects of COVID-19 and provide appropriate management and care for patients, particularly those in vulnerable groups.

CRITICAL REVIEWS IN MICROBIOLOGY (2023)

Review Immunology

Multicountry Review of Streptococcus pneumoniae Serotype Distribution Among Adults With Community-Acquired Pneumonia

Lindsay R. Grant, Elizabeth Begier, Christian Theilacker, Rachid Barry, Cassandra Hall-Murray, Qi Yan, Veneta Pope, Michael W. Pride, Luis Jodar, Bradford D. Gessner

Summary: Nonbacteremic community-acquired pneumonia is a major presentation of severe pneumococcal disease in adults. Urinary antigen detection can guide the use of higher valency pneumococcal conjugate vaccines by detecting the serotypes causing pneumococcal CAP.

JOURNAL OF INFECTIOUS DISEASES (2023)

Review Microbiology

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine

Estelle Meroc, Mark A. A. Fletcher, Germaine Hanquet, Mary P. E. Slack, Marc Baay, Kyla Hayford, Bradford D. D. Gessner, Lindsay R. R. Grant

Summary: Higher valency pneumococcal conjugate vaccines (PCV15 and PCV20) have been developed to tackle the disease burden caused by non-vaccine serotypes. This review provides an overview of the epidemiological characteristics of serotypes beyond PCV13, analyzing their association with different diseases and their antimicrobial non-susceptibility. The findings can contribute to informed decision-making regarding the choice and use of higher valency PCVs.

MICROORGANISMS (2023)

Meeting Abstract Respiratory System

ADULT HOSPITALISED COMMUNITY ACQUIRED PNEUMONIA INCIDENCE IN BRISTOL: COMPARISON OF RETROSPECTIVE ICD-10 BASED ANALYSIS AND PROSPECTIVE STUDY DATA

J. A. Campling, E. Begier, M. Lahuerta, A. Vyse, J. Southern, S. Valluri, C. Hyams, A. Finn, M. P. E. Slack, B. D. Gessner, G. Ellsbury

THORAX (2022)

Article Medicine, Research & Experimental

Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2

Elena Mitsi, Jesus Reine, Britta C. Urban, Carla Solorzano, Elissavet Nikolaou, Angela D. Hyder-Wright, Sherin Pojar, Ashleigh Howard, Lisa Hitchins, Sharon Glynn, Madlen C. Farrar, Konstantinos Liatsikos, Andrea M. Collins, Naomi F. Walker, Helen C. Hill, Esther L. German, Katerina S. Cheliotis, Rachel L. Byrne, Christopher T. Williams, Ana Cubas-Atienzar, Tom E. Fletcher, Emily R. Adams, Simon J. Draper, David Pulido, Rohini Beavon, Christian Theilacker, Elizabeth Begier, Luis Jodar, Bradford D. Gessner, Daniela M. Ferreira

Summary: This study investigated the relationship between SARS-CoV-2 and Streptococcus pneumoniae in different populations, and found that pneumococcal infection reduces host immune responses to the virus.

JOURNAL OF CLINICAL INVESTIGATION (2022)

No Data Available